Shilajit vs Rhodiola Rosea: An Honest Comparison
Shilajit and Rhodiola rosea get grouped together often, both sold as "adaptogens" for energy and stress. They come from different traditions, different plants and geology entirely, and have genuinely different evidence bases behind them. This comparison works through what each actually has real human research for, where the evidence is thinner than the marketing suggests, and where the two overlap or diverge.
In this article
Key takeaways
- Rhodiola has more human trials on fatigue and mood than shilajit, but a large share of them come from one manufacturer-linked research group using the same branded extract.
- Shilajit has a real human trial on testosterone; Rhodiola's own best modern review admits its hormonal effects are preclinical only.
- Neither has a verified, high-quality human trial proving cognitive or memory enhancement in healthy people.
What each one actually is
Shilajit is a mineral-rich resin that exudes from high-altitude rock in the Himalayas, formed from decomposed organic matter interacting with mineral-rich rock over long periods, and used in Ayurvedic medicine. Rhodiola rosea, also called golden root or arctic root, is a flowering plant that grows in cold, high-altitude regions of Russia, Scandinavia and Central Asia, with a long history in Russian, Scandinavian and Central Asian folk medicine for endurance, cold tolerance and fatigue. Most Rhodiola clinical trials use a specific standardised extract called SHR-5, made by one manufacturer, which matters for how independent the research base actually is.
Fatigue and stress: Rhodiola's strongest area, with a real caveat
Several double-blind, placebo-controlled human trials have tested Rhodiola for fatigue: 20 days in stressed students, a crossover trial in physicians working night shifts, a single-dose trial in cadets, and a 28-day trial in adults with diagnosed fatigue syndrome that also tracked cortisol response. Results were generally positive on fatigue indices.
A 2012 systematic review of 11 studies found a more mixed picture: only 2 of 6 physical-fatigue trials and 3 of 5 mental-fatigue trials reported Rhodiola effective, and the review stated plainly that the included studies "exhibit either a high risk of bias or have reporting flaws." It is also worth knowing that most of these trials, across several different research teams, use the same branded SHR-5 extract from a single manufacturer, which is a real pattern worth being transparent about rather than treating each trial as fully independent replication.
Shilajit's own human energy evidence is different in character: a small, manufacturer-funded pilot study found gene expression changes related to muscle repair after 12 weeks, with no placebo comparison and no direct measure of felt energy.
Exercise performance
Rhodiola has a real, if inconsistent, exercise research base. An acute dose improved time-to-exhaustion and VO2 peak in one small trial, though the same study found no benefit after 4 weeks of continuous dosing. A separate trial found an acute dose improved cycling time-trial performance and lowered perceived exertion. A 2023 systematic review of 13 trials (263 participants) found acute dosing helped endurance performance and perceived exertion, chronic dosing helped anaerobic but not endurance performance, and most included studies carried unclear-to-high bias risk.
Shilajit's exercise evidence is narrower but comes from an unrelated research group: a placebo-controlled trial in 63 young, fit men found a branded shilajit extract helped preserve muscular strength after a fatigue protocol over 8 weeks.
Mood and anxiety: a genuine point of difference
This is an area where Rhodiola has real trial data that shilajit's current evidence base does not include at all. A 6-week trial in adults with mild to moderate depression found significant improvement on standard depression scales compared with placebo. A more rigorous, independently funded trial compared Rhodiola against the antidepressant sertraline and placebo over 12 weeks: the difference between Rhodiola and placebo was not statistically significant, though Rhodiola caused noticeably fewer side effects than sertraline. This is a more honest, more equivocal result than the "works like an antidepressant with fewer side effects" framing it is often given in marketing.
Cognitive claims: a shared weak spot
Neither herb has a verified, high-quality human trial demonstrating memory or cognitive enhancement in healthy, rested adults. A couple of Rhodiola trials touch on attention and reaction-time measures, but they test Rhodiola combined with other herbs, not Rhodiola alone, which makes it impossible to isolate its individual effect. Shilajit's cognitive evidence, per our full evidence review, is limited to laboratory biochemistry, not a human trial. Treat general "boosts brainpower" claims for either as unproven.
Safety
European regulatory guidance classifies Rhodiola as a traditional herbal product with limited safety data, generally not recommended in pregnancy or for under-18s, and official guidance from the US National Centre for Complementary and Integrative Health describes it as possibly safe for up to 12 weeks of use, with insufficient evidence for longer-term safety. Mild reported side effects across trials include dizziness and dry mouth. Rhodiola may theoretically interact with medications affecting serotonin or monoamine oxidase, which is a reasonable reason to check with a healthcare professional if you take other medication. Shilajit's main documented safety issue is different in kind: heavy metal risk in unpurified raw resin, which is why independent, batch specific testing matters. See our full shilajit safety guide for detail.
Comparison table
| Claim area | Shilajit | Rhodiola |
|---|---|---|
| Testosterone | Human RCT one trial, unreplicated | None found preclinical only per its own reviews |
| Fatigue / energy | Human pilot manufacturer funded, no placebo | Multiple RCTs mixed results, largely one manufacturer's extract |
| Exercise performance | Human RCT one trial, young fit men | Multiple RCTs acute dosing more consistent than chronic |
| Mood / anxiety | None found not in current evidence base | Human RCTs real trials, best one statistically inconclusive vs placebo |
| Cognition / memory | In vitro only | None found isolated Rhodiola, no verified human trial |
The honest verdict
These are not interchangeable products competing for the same job. Rhodiola has a broader, if unevenly independent, human trial base for fatigue, mood and exercise. Shilajit's narrower evidence base includes a real testosterone trial that Rhodiola simply does not have an equivalent for. Both share the same genuine weak spot on cognition. Neither should be marketed with claims stronger than what their actual trials show.
FAQ
Is Rhodiola better researched than shilajit?
It has more human trials overall, but a large share use the same manufacturer's branded extract, which limits how independent that body of evidence really is. Shilajit's smaller evidence base comes from more varied research groups.
Can I take shilajit and Rhodiola together?
We are not aware of documented safety concerns specific to combining them, but neither is a substitute for medical advice, and anyone on medication, particularly anything affecting serotonin, should check with a healthcare professional first.
Does either genuinely improve testosterone?
Shilajit has one real, unreplicated human trial showing an increase in healthy men. Rhodiola's hormonal effects are, per its own most favourable modern review, based on animal data only.
References
- Spasov AA, et al. Phytomedicine. 2000;7(2):85 to 89. PMID 10839209.
- Darbinyan V, et al. Phytomedicine. 2000;7(5):365 to 371. PMID 11081987.
- Shevtsov VA, et al. Phytomedicine. 2003;10(2 to 3):95 to 105. PMID 12725561.
- De Bock K, et al. Int J Sport Nutr Exerc Metab. 2004;14(3):298 to 307. PMID 15256690.
- Darbinyan V, et al. Nord J Psychiatry. 2007;61(5):343 to 348. PMID 17990195.
- Olsson EM, et al. Planta Med. 2009;75(2):105 to 112. PMID 19016404.
- Noreen EE, et al. J Strength Cond Res. 2013;27(3):839 to 847. PMID 23443221.
- Ishaque S, et al. BMC Complement Altern Med. 2012;12:70. PMID 22643043.
- Mao JJ, et al. Phytomedicine. 2015;22(3):394 to 399. PMID 25837277.
- Sanz-Barrio PM, Quintela JC. Phytother Res. 2023;37(10):4414 to 4428. PMID 37495266.
- Pandit S, et al. Andrologia. 2016;48(5):570 to 575. DOI: 10.1111/and.12482.
- Keller JL, et al. J Int Soc Sports Nutr. 2019;16(1):3.
Some figures above are drawn from published abstracts rather than full text where publisher access was restricted; noted transparently in our internal research record.